Multiplexed assessment of the Southwest Oncology Group-directed intergroup breast cancer trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome

Malini Harigopal, William E. Barlow, Greg Tedeschi, Peggy L. Porter, I. Tien Yeh, Charles Haskell, Robert Livingston, Gabriel N. Hortobagyi, George Sledge, Charles Shapiro, James N. Ingle, David L. Rimm, Daniel F. Hayes

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Fingerprint Dive into the research topics of 'Multiplexed assessment of the Southwest Oncology Group-directed intergroup breast cancer trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome'. Together they form a unique fingerprint.

Medicine & Life Sciences